Borek DM, et al. - In this retrospective, non-interventional study, authors analyzed 1158 subjects to explore the patient characteristics predictive of persistence and also to examine the long-term persistence with denosumab among patients treated for osteoporosis. The 36-month persistence overall was 50.7% in a Kaplan-Meier survival analysis. They noticed 64.2% of the cohort of net persistence (defined by receiving seven injections in the allowable time frame). They observed an association of previous vertebral fractures and recent osteoporosis therapy with higher persistence whereas age more than 75 years was correlated with non-persistence. They recorded the availability of reasons for discontinuation in 91.6% of non-persistent cases and categorized to include the 10 most common explanations.